Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Jul 09, 2020

Results of Maruho’s Phase III Study with Chugai’s Nemolizumab for Atopic Dermatitis Published in The New England Journal of Medicine Online

TOKYO, July 9, 2020 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that results from a phase III study conducted by Maruho Co., Ltd. investigating nemolizumab in atopic dermatitis patients 13 years of age or older with moderate-to-severe pruritus were published in The New England Journal of Medicine Online. Nemolizumab is an anti-interleukin-31 (IL-31) receptor A humanized monoclonal antibody created by Chugai.
Article: https://www.nejm.org/doi/full/10.1056/NEJMoa1917006.

Press release by Maruho issued on July 9, 2020:
Maruho Announces New England Journal of Medicine Publication of Results from Phase 3 Clinical Study (Comparative Study) in Japan of Nemolizumab for the Treatment of Atopic Dermatitis
https://www.maruho.co.jp/english/release/nek5p40000005vzg-att/20200709_pr_eng.pdf

[Note]
Nemolizumab Achieves Primary Endpoint in Phase 3 Clinical Study (Comparative Study) in Japan for the Treatment of Atopic Dermatitis (Press release by Maruho issued on Apr 18, 2029)
https://www.maruho.co.jp/english/release/nek5p40000004lm8-att/20190418_pr_eng.pdf

Chugai and Maruho Announce License Agreement of Nemolizumab (CIM331), a Novel Biologic in the Skin Disease Area for the Japanese Market (Press release issued on Sep 28, 2016)
https://www.chugai-pharm.co.jp/english/news/detail/20160928150000_121.html

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Toshiya Sasai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top